Why this Houston medical device innovator is pumped up for the first total artificial heart

HOUSTON INNOVATORS PODCAST EPISODE 248

Dr. William Cohn is the chief medical officer for BiVACOR, a medical device company creating the first total artificial heart. Photo via TMC

It's hard to understate the impact Dr. William Cohn has had on cardiovascular health as a surgeon at the Texas Heart Institute or on health care innovation as the director of the Center for Device Innovation at the Texas Medical Center. However, his role as chief medical officer of BiVACOR might be his most significant contribution to health care yet.

The company's Total Artificial Heart is unlike any cardiovascular device that's existed, Cohn explains on the Houston Innovators Podcast. While most devices are used temporarily for patients awaiting a heart transplant, BiVACOR's TAH has the potential to be a permanent solution for the 200,000 patients who die of heart failure annually. Last year, only around 4,000 patients were able to receive heart transplants.

"Artificial hearts historically have had bladders that ejected and filled 144,000 times a day. They work great for temporary support, but no one is suggesting they are permanent devices," Cohn says on the show.

The difference with BiVACOR's device is it abandons the bladder approach. Cohn explains that as assist pumps evolved — something his colleague, Dr. Bud Frasier, had a huge impact on — they featured new turbine and rotor technology. Daniel Timms, BiVACOR's founder and CTO, iterated on this technology beginning when he was a postdoctoral student at Queensland University of Technology in Australia.

"BiVACOR is the first artificial heart that leverages what we learned from that whole period — it has no bladders, it has no valves. It has one moving part, and that moving part is suspended in an electromagnetic field controlled by a computer and changed thousands of times a second," Cohn says. "It will never wear out, and that's why we think it's the world's first total artificial heart."

The company is seeing momentum, celebrating its first successful human implantation last month. The device was used for eight days on a patient at Baylor St. Luke’s Medical Center before the patient received a heart transplant.

Cohn says that BiVACOR has plans to use the TAH as "bridge-to-transplant" device in several other surgeries and expects to get FDA approval for that purpose in the next three to four years before working toward clearance for total artificial heart transplants.

Cohn has worked to support medical device startups at CDI at TMC for the seven years it has existed — first under Johnson and Johnson and then under TMC when it took the program over. He describes the center and its location as the ideal place for developing the future of health care, with Houston rising up to compete with regions known for medical device success — both coasts and Minnesota.

"Being in the shadow of the largest medical center on the planet — 106,000 employees show up there every 24 hours," Cohn says, "if you want to innovate, this is the place to do it."

From Your Site Articles
Revisiting a conversation with Dr. Joseph Rogers, president and CEO of the Texas Heart Institute, on the Houston Innovators Podcast. Photo via texasheart.org

Play it back: How this Houstonian is leading heart health innovation

HOUSTON INNOVATORS PODCAST EPISODE 246

Heart health innovation is at a major moment in history — and Houston is at the center of it.

Last summer, Dr. Joseph Rogers, president and CEO of the Houston-based Texas Heart Institute, joined the Houston Innovators Podcast to share how he came to be at the helm of THI, as well as the incredible technologies the institute is working on to address heart failure, a global epidemic affecting at least 26 million people worldwide, 6.2 million adults in the U.S.

This month, one of THI’s technologies reached a major milestone. BiVACOR, a Houston company successfully implanted the company's first Total Artificial Heart in a human. The device was implanted in the patient on July 9. Eight days later, a donor heart became available and was transplanted into the patient, removing the TAH, establishing the device as a successful bridge-to-heart-transplant solution for patients, THI reported.

In addition to this breakthrough in health tech, THI is focused on addressing Cardiometabolic Syndrome at a new conference on Friday, August 23, in Houston. The full-day symposium will take place in collaboration with Arianna Huffington, the founder and CEO of Thrive Global. Dr. Rogers is co-directing the program with Dr. Stephanie Coulter, medical director for THI Center for Women’s Heart & Vascular Health.


In the episode, Rogers explains why he's bullish on Houston and THI leading heart health innovation alongside other health care organizations — nonprofits, universities, local government — to collaborate in ways never been done before. And THI is dedicated to this mission.

"We should act as a convener," Rogers says. "Houston is the place to do this.

"The reason I think this is such an important community to address this problem is it's the most diverse city in the United States. And I've never lived anywhere or heard of another city that I was so convinced believed they could do anything they set their minds to. It's about making the community aware of the problem and a potential solution — and then working on trying to solve it," he continues. "But I think all of the pieces are here to show the world how to do this at a community level."

Emerson Perin of the Texas Heart Institute, recently published the largest clinical trial of cell therapy for patients with chronic heart failure to-date included 580 patients at 52 sites throughout North America. Photo via texasheart.org

Houston health care leader on a mission to innovate an end to heart failure

cardiology cured

Emerson Perin’s end goal isn’t to treat heart failure. The medical director of The Texas Heart Institute says that he has his sights set firmly on curing the malady altogether. And, with the power of innovation and a strong team, the Houston-based cardiologist has a good chance of meeting his objective.

Perin first came to THI for fellowship training in 1988, following his residency in Miami and medical school in his birthplace of Brazil.

“This is a very special place,” the physician and researcher, whose titles also include director for THI’s Center for Clinical Research and vice president for medical affairs, tells InnovationMap. “It has a worldwide-reaching reputation. I’ve always liked research and this is a great place in terms of innovation and practicing high-level cardiology.”

For decades, Perin has followed in THI founder Denton Cooley’s footsteps with world-changing research. In 2001, the founding medical director of THI’s Stem Cell Center was the first person to inject stem cells into a failing human heart. It led to a trial of 17 patients that year.

“A couple of the patients did remarkably well — more than you could ever expect. These guys who couldn’t’ walk across the room pretty much were jogging on the beach. That gave me the initial insight that this works,” Perin recalls.

What exactly is heart failure? The term refers to the condition of a heart that can’t pump enough blood to sustainably power the body through oxygenation of the tissues from blood flow. It may sound like a death sentence, but with appropriate care, it can usually be managed with medicines and if worsening occurs, devices and, ultimately, heart transplantation.

And Perin is proving that there’s a lot of life ahead for heart failure patients. Earlier this year, he published another groundbreaking clinical trial, DREAM-HF. The largest clinical trial of cell therapy for patients with chronic heart failure to-date included 580 patients at 52 sites throughout North America.

With the goal of getting a new cell therapy approved for heart failure, the primary endpoint was to prove that the therapy could prevent recurrent hospitalizations.

“It was a total negative,” says Perin. That’s because the cells don’t have a decongestant effect such as the medicines currently used to treat heart failure.

But that doesn’t mean that the trial was a failure. Quite the opposite. That’s because Perin and his team proved something else: The trial was able to prove that there was significant improvement in patients with inflammation. After those patients were injected with mesenchymal precursor cells (MPC), they showed a 70-percent reduction in heart attacks and strokes. Cardiovascular deaths also decreased.

These are blockbuster numbers, and big news for patients dealing with heart failure. What it means is that the cells addressed a different aspect of heart failure that until now had been left untreated which was the inflammation — how heart failure starts and what keeps it going.

So what’s next? Going to the FDA.

“They said, ‘We can’t approve it with one trial, but we’ll approve it with two,’” says Perin.

This time, his primary endpoint will be tailored to suit the positive outcome he knows he’ll be able achieve. This next round will begin in 2024.

Once the FDA approves a new catheter system for injecting the heart with stem cells and genes, the team will proceed with new studies. Gene therapy will be another frontier for Perin — and patients with heart failure.

“I think the combination of cells and genes is even more powerful,” he says. “That will help save lives in a completely new way and do away with heart failure.”

Perin's work is just one piece of the puzzle, and Dr. Joseph Rogers, who was appointed president and CEO of THI in 2021, is leading the organization's initiative in several ways. THI, recently buoyed by a $32 million donation from a patient — the largest charitable donation in its history — is exploring several innovative therapeutics, devices, and treatments.

THI recently received a two-year, $1.14 million grant from The National Heart, Lung, and Blood Institute to develop a novel, first-in-class drug to treat the cardiovascular disease that arises from atherosclerosis. Another THI innovator, Camila Hochman-Mendez — along with her research team — is studying the effects of regenerative medicine on hearts.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

5 must-know fall application deadlines for Houston innovators

apply now

Editor's note: As fall reaches full swing, Houston's innovation scene is calling on the latest batch of founders and startups looking to make a difference. A number of accelerators have opened applications. Read below to see which might be a good fit for you or your venture. And take careful note of the deadlines. Please note: this article may be updated to include additional information and programs.

Did we miss an accelerator or competition accepting applications? Email innoeditor@innovationmap.com for editorial consideration.

Texas Life Science Forum

Deadline: Oct. 2

Details: Ventures can apply to present at the 15th annual Texas Life Science Forum, hosted by BioHouston and Rice Alliance. Participants will meet during office hours with venture capitalists, tech scouts, corporate venture groups and angel investors, and present their pitches in a public forum. Pitches take place on Nov. 10 and office hours are held Nov. 11. Find more information here.

Greentown Lab's Go Make 2027: Advanced Carbon Materials with ExxonMobil

Deadline: Oct. 9

Details: Greentown Labs is seeking applications from startups developing novel carbon-based technologies for its latest Go Make cohort in conjunction with ExxonMobil. The structured accelerator is designed to facilitate validation activities and explore potential long-term collaborations with Exxon, according to Greentown. Founders will have the opportunity to engage directly with industry leaders to test, validate and scale their carbon technologies in real commercial contexts. The program tentatively starts on Jan. 20, 2027 and concludes June 16, 2027. Find more information here.

Activate's U.S. Fellowship Cohort 2027

Deadline: Oct. 30

Details: Activate supports scientists at "the outset of their entrepreneurial journey." It partners with U.S.-based funders and research institutions to support its fellows in developing high-impact technology. Its fellows receive a living stipend, research and development funding, connections from Activate's robust network of mentors and access to a curriculum specific to the program for two years. Applicants must have a bachelor’s degree and 4-plus years of post-baccalaureate scientific research, engineering or technology development experience. Their work must be based in the physical or biological sciences or related engineering disciplines. Find more information here.

Rice Innovation Fellows

Deadline: Oct. 30

Details: The Liu Idea Lab for Innovation and Entrepreneurship (Lilie)'s Rice Innovation Fellows program supports Rice Ph.D. students and postdocs in turning their research into real-world ventures. Participants receive $10,000 in translational research funding, co-working space and personalized mentorship. Candidates from all Rice engineering and science-related disciplines are encouraged to apply. Find more information here.

The TMC's Accelerator for Cancer Therapeutics

Deadline: Oct. 30

Details: Texas-based ventures and researchers developing a cancer therapeutics project can apply to this accelerator funded by the Cancer Prevention and Research Institute of Texas. The nine-month program runs February-September 2027 and focuses on market research, FDA regulations, intellectual property, licensing, finance, fundraising, legal and other critical areas for cancer-related ventures. Participants will complete the program with at least one grant submission and have the option to pitch to investors, corporate partners, media and other influential guests. Find more information here.

Houston college joins inaugural workforce accelerator supported by Google

hands-on training

Houston City College (HCC) is one of 15 community colleges from around the country to be selected for the first-ever Workforce Futures Accelerator.

The three-year effort is supported by Google.org, the tech company’s philanthropic arm, and led by the Association of Community College Trustees (ACCT), a non-profit educational organization that represents over 500 community, junior, and technical colleges. The accelerator focuses on helping colleges embed virtual, employer-sponsored training opportunities into short-term workforce training programs, giving participants access to opportunities that they might otherwise receive through internships or other "work-based learning" stints.

"The Workforce Futures Accelerator reflects the Houston City College mission of offering a high-quality, affordable education for workforce training and career development," Pretta VanDible Stallworth, HCC trustee and chair-elect of the ACCT board of directors, said in a news release. "Advancing student success and creating pathways to opportunities ensures that our students are well equipped to succeed and build a secure future in today's economy.”

Through the accelerator, HCC is tasked with fusing online project-based learning opportunities with its workforce education programs. The idea is to give students hands-on experiences working on projects sponsored by employers, allowing them to gain real-world knowledge in the process.

HCC will select two workforce programs that meet the accelerator’s criteria and insert into them into coursework. In the second and third year of the accelerator, the selected colleges are expected to scale the programs by adding instructors and programs to develop a network of to support their continued implementation.

“Participation by HCC will strengthen how we provide students with career-connected learning experiences that complement their classroom education and align with the needs of employers,” HCC Chancellor Margaret Ford Fisher added in the news release. “We are focused on ‘future forward’ strategies to meet the present and future needs of our region’s businesses.”

Two other Texas colleges were chosen to participate in the accelerator: Lamar Institute of Technology in Beaumont and Grayson College in Denison.

The remaining cohort includes:

  • Bergen Community College in Paramus, New Jersey
  • Central Louisiana Community College in Alexandria, Louisiana
  • Clark State College in Springfield, Ohio
  • Great Basin College in Elko, Nevada
  • Heartland Community College in Normal, Illinois
  • Hudson County Community College in Jersey City, New Jersey
  • Manchester Community College in Manchester, New Hampshire
  • Mesa Community College in Mesa, Arizona
  • Mohave College in Kingman, Arizona
  • San Joaquin Delta Community College in Stockton, California
  • San Juan College in Farmington, New Mexico
  • West Virginia University Parkersburg in Parkersburg, West Virginia

New report ranks Texas among top 10 states where AI could disrupt jobs

AI Workforce

A new nationwide report examining where AI could "reshape" the most jobs has ranked Texas No. 9 among the most at-risk states for AI job disruption.

The new SmartAsset report compared all 50 states and the District of Columbia to calculate the estimated percent of the workforce employed in the 26 occupations with the highest AI exposure, as determined by June 2026 research by the Virginia Economic Information and Analytics Division.

The findings revealed that 500,000 Texas workers, or 3.55 percent of the total workforce, are employed in occupations with "high exposure to potential AI disruption."

This also places the Lone Star State as the 9th most at-risk state in the U.S. where AI exposure can lead to "declining hiring demand, wage pressure, task automation, and other forms of disruption."

"States with larger concentrations of highly exposed occupations could experience more pronounced labor-market changes, particularly in roles where core tasks are more vulnerable to AI-driven restructuring," the report's author wrote.

Texas' biggest cities, like Houston and Austin, are known for their thriving tech and business industries, and the study noted that many of the occupations within those sectors are the most at risk. The Virginia Economic Information and Analytics Division said the top five most AI-exposed occupations in the U.S. are: mathematicians, proofreaders, correspondence clerks, court reporters, and media and communication workers. Additionally, computer programmers, database administrators, web developers, telephone operators, and communications equipment operators round out the top 10 most at-risk positions.

These are the 16 remaining occupations most exposed to AI disruption, in order:

  • Data Entry Keyers
  • Statistical Assistants
  • Office Support Workers
  • Interpreters and Translators
  • Database Architects
  • Software Quality Assurance Analysts
  • Medical Transcriptionists
  • Software Developers
  • Writers and Authors
  • Payroll Clerks
  • Web Designers
  • Miscellaneous Computer Occupations
  • Insurance Claims Processors
  • Telemarketers
  • Computer Numerically Controlled Tool Programmers
  • Bookkeeping and Accounting Clerks

A separate SmartAsset report from April 2026 found about 20.5 percent of Texas workers use AI to do their jobs in some capacity. That trend will continue to shift further as employers and employees choose to adopt — or reject — AI implementation.

Across the U.S., Washington topped the list as the state with the highest concentration of AI-exposed jobs, with nearly 5.7 percent of the state's workforce employed in the 26 most at-risk positions. SmartAsset said Washington's high prevalence of technology companies is a significant factor that skyrocketed the state to the top of the list.

"Home to major technology companies including Microsoft, Amazon, T-Mobile and Expedia, the state has large numbers of computer programmers and software developers, two occupations with high exposure," the report said.

Meanwhile, Mississippi ranked No. 51 with the lowest concentration of AI-exposed jobs in the nation. About 22,500 workers in Mississippi, or 1.93 percent of its workforce, are at risk for AI disruption.

The top 10 states where AI could reshape the most jobs are:

  • No. 1 – Washington
  • No. 2 – Virginia
  • No. 3 – District of Columbia
  • No. 4 – California
  • No. 5 – Utah
  • No. 6 – Maryland
  • No. 7 – Colorado
  • No. 8 – New Hampshire
  • No. 9 – Texas
  • No. 10 – North Carolina
---

This article originally appeared on CultureMap.com.

View All Listings